| 01.06.22 | With Alnylam beh ind him, Maraganore’s 2nd act begins; Sanofi says sayonara to Sangamo cell therapy deal

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

2 jahre vor

Html
Text

Phase 1 Trials: Strategies for Site Selection and Dose-Escalation

Designing and executing an effective Phase 1 trial for a novel investigational oncology product can be challenging.Download our white paper for key considerations on site selection and dose-escalation design strategies in early-phase oncology trials. Premier Research. Built for Biotech℠

Today's Rundown

With Alnylam in rear view, Maraganore wants to be a biotech multiplier, matchmaker and mentor Sanofi tears up Sangamo cell therapy deal in pivot to off-the-shelf approaches Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs Novartis taps Alnylam for ambitious push to fix liver function Eli Lilly taps Entos' delivery tech in $50M-plus nucleic acid pact Eikon Therapeutics snares $500M series B, pinning constellation of biotech stars to its upper ranks Annexon shares dip 30% as patient dropouts dog midphase Huntington's trial Ultragenyx granted go-ahead to up doses for Angelman antisense therapy that stalled after safety issues Fierce is looking for the biggest Rising Stars in Health Tech Pfizer, Roche, AstraZeneca and J&J face newly revived lawsuit claiming they funded terrorism in Iraq Unions go to court to get OSHA to release permanent COVID-19 protection standard With sexually transmitted infections off the charts, California pushes at-home tests

Featured Story

With Alnylam in rear view, Maraganore wants to be a biotech multiplier, matchmaker and mentor

By Annalee Armstrong

After 19 years at the helm of Alnylam, John Maraganore, Ph.D., is not wasting any time getting started on the next phase of his career.

Webinar: How to choose the appropriate pre-filled syringe and enhanced delivery system for your product

Wednesday, January 19 | 11 am ET / 8am PT

In an environment that calls for more convenient delivery systems, we will guide you on how to make the right choice for your product. This webinar will cover selection criteria for pre-filled syringes and enhanced delivery systems. Register to learn more.

Sanofi tears up Sangamo cell therapy deal in pivot to off-the-shelf approaches

By Nick Paul Taylor

Sanofi is rethinking its approach to genomic medicines. Having worked with Sangamo Therapeutics on personalized cell therapies, Sanofi has decided to scrap the deal and shift its focus to allogeneic universal genomic medicine approaches.

Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs

By Annalee Armstrong

Amgen wants its future drugs to be multispecific, and so the biopharmaceutical company selected Generate Biomedicines for a $1.9 billion biobucks deal to initially create five programs across several diseases.

Novartis taps Alnylam for ambitious push to fix liver function

By Nick Paul Taylor

More than a decade after severing ties to RNAi pioneer Alnylam, Novartis has returned to the deal table for an ambitious early-stage collaboration to restore liver function in patients with end-stage disease.

Eli Lilly taps Entos' delivery tech in $50M-plus nucleic acid pact

By Fraiser Kansteiner

Eli Lilly has picked up exclusive right to Entos’ Fusogenix nucleic acid delivery technology, which it will use to research, develop and potentially sell nucleic acid-based therapeutics against targets in the central and peripheral nervous systems.

Eikon Therapeutics snares $500M series B, pinning constellation of biotech stars to its upper ranks

By Fraiser Kansteiner

Eikon Therapeutics, the drug discovery startup with a former Merck & Co. research chief at the helm, has appointed a pantheon of biotech veterans on its quest to take its live-cell imaging platform to the next level.

Annexon shares dip 30% as patient dropouts dog midphase Huntington's trial

By Annalee Armstrong

Annexon found out the hard way that investors do read the fine print. Despite the small biotech reporting “promising” interim results from a midphase Huntington’s disease trial, the company saw its shares plummet 30%.

Ultragenyx granted go-ahead to up doses for Angelman antisense therapy that stalled after safety issues

By Annalee Armstrong

Ultragenyx Pharmaceutical and partner GeneTx Biotherapeutics have been given the go-ahead to up the dose in a phase 1/2 Angelman syndrome trial of antisense treatment GTX-102 that was previously paused after some patients temporarily lost the ability to walk.

Fierce is looking for the biggest Rising Stars in Health Tech

By Conor Hale,Heather Landi

We’re searching for the engineers and designers who are looking to deliver on the beneficial potential of AI and new technologies in healthcare.

Pfizer, Roche, AstraZeneca and J&J face newly revived lawsuit claiming they funded terrorism in Iraq

By Kevin Dunleavy

Pharmaceutical giants Pfizer, AstraZeneca, Roche and Johnson & Johnson will have to answer to charges that they paid bribes to win healthcare contracts in Iraq and in the process funded terrorists who killed Americans during the war. This week, a U.S. appeals court revived a lawsuit that was filed in 2017 and dismissed three years later.

Unions go to court to get OSHA to release permanent COVID-19 protection standard

By Robert King

Nursing and labor unions filed a petition in a federal appeals court to force OSHA to install a permanent standard to protect front-line health workers from COVID-19.

With sexually transmitted infections off the charts, California pushes at-home tests

By Rachel Bluth, Kaiser Health News

California has become the first state to require health insurance plans to cover at-home tests for sexually transmitted infections such as HIV, chlamydia and syphilis.

Webinar: A Collaborative Approach to Complex Chemistry

Wednesday, January 12, 2022 | 11am ET / 8am PT

Complex therapeutics demand complex chemistry expertise. Discover how the right partner can help you overcome complex chemistry challenges through extensive experience, specialised technologies, and true scientific collaboration. Register now.